- Home
- YSXT vs AVTX Comparison
YSXT vs AVTX Comparison
Compare YSXT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | AVTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | 33 |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 888.6M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | YSXT | AVTX |
|---|---|---|
| Price | $1.36 | $16.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 32.5K | ★ 856.9K |
| Earning Date | 02-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $0.50 | $10.70 |
| 52 Week High | $3.14 | $24.27 |
Technical Indicators
Market Signals| Indicator | YSXT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 39.35 |
| Support Level | $0.98 | $15.29 |
| Resistance Level | $1.51 | $16.80 |
| Average True Range (ATR) | 0.11 | 1.00 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 69.23 | 23.14 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.